|
(Health-NewsWire.Net, July 20, 2024 ) InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global In-Silico Drug Discovery Market Size, Share & Trends Analysis By Products (Software, Software-as-a-Service (SaaS), Consultancy-as-a-Service), By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials), By Technology(Artificial Intelligence, Graphics Processing Unit (GPU)), By Software Type (Molecular Modelling And De Novo Drug Design Software, Pharmacophore Modelling Software), By End User (Contract Research Organizations, Pharmaceutical And Biopharmaceutical Companies, Academic And Research Institutes)- Market Outlook And Industry Analysis 2031"
Download Free Sample Report: https://insightaceanalytic.com/request-sample/2223
In-silico drug discovery has transformed pharmaceutical research by harnessing computational methods to identify and optimize potential drug candidates. Through techniques like virtual screening and molecular docking, researchers can swiftly sift through vast libraries of compounds to pinpoint those most likely to interact effectively with specific biological targets. This accelerates the early stages of drug discovery by focusing resources on promising candidates, thereby reducing time and costs traditionally associated with experimental screening. Moreover, in-silico methods such as QSAR modeling and molecular dynamics simulations refine lead compounds for enhanced potency, selectivity, and favorable drug-like properties. These predictive tools not only streamline the drug development process but also contribute to reducing reliance on animal testing by allowing researchers to assess potential efficacy and safety profiles early on.
The market for in-silico drug discovery offers a range of products and services tailored to meet the needs of pharmaceutical companies and research institutions. This includes sophisticated software platforms for molecular modeling and virtual screening, cloud-based solutions that provide scalable access to computational tools, and consultancy services staffed by experts in computational biology and drug discovery. Additionally, advancements in artificial intelligence and machine learning have further accelerated in-silico drug discovery by improving predictive modeling accuracy and enabling deeper insights from complex biological data. These technologies continue to drive innovation in drug development, offering new opportunities for discovering novel therapies and repurposing existing drugs for new indications, all while adhering to ethical considerations and regulatory standards.
List of Prominent Players in the In-Silico Drug Discovery Market:
Aragen Life Sciences Pvt. Ltd.
Curia Global, Inc.
Certara, USA.
Charles River
Chemical Computing Group ULC.
Collaborative Drug Discovery Inc.
Dassault Systemes
e-therapeutics plc.
Evotec
Insilico Medicine
Ligand Pharmaceuticals Incorporated
Numerate, Inc.
PerkinElmer Inc.
Schrφdinger, Inc.
Selvita
Simulations Plus
Tracxn Technologies
WuXi AppTec
Others
Market Dynamics:
Drivers-
The escalating costs associated with traditional drug development methods, particularly in clinical trials, have driven pharmaceutical companies to adopt in-silico drug discovery techniques. In-silico approaches offer substantial cost savings by minimizing the number of compounds that require synthesis and experimental testing, thus streamlining the drug development process from virtual screening to molecular modeling.
Advances in computing power have further enhanced these capabilities, facilitating faster simulations and big data analyses. Moreover, the increasing adoption of cloud-based applications provides researchers with scalable computational resources, fostering collaboration, data sharing, and access to specialized tools. This convergence of cost-saving benefits and technological advancements underscores the pivotal role of in-silico drug discovery in accelerating timelines and improving efficiency in pharmaceutical research and development.
Challenges:
In-silico drug development faces regulatory challenges in validating computational models and integrating them into drug discovery practices. Limited availability of high-complexity testing centers and high costs are practical obstacles. Despite its potential to accelerate early-stage development, bridging the gap with experimental validation remains critical for ensuring drug safety and efficacy.
Regional Trends:
The demand for in-silico drug discovery in North America is propelled by the urgent need for treatments for rare diseases like Lou Gehrig's disease and cystic fibrosis, driven by a sizable patient population in the U.S. seeking innovative therapies. The region benefits from a flexible regulatory environment established by the U.S. FDA, which supports the adoption of computational methods in drug development through streamlined co-development processes. North America's advanced infrastructure and robust partnerships among service providers and manufacturers further bolster the market. Key players like Schrodinger, Dassault Systθmes, and Certara, headquartered in the region, contribute significantly to research and development efforts, enhancing the efficacy and accessibility of in-silico drug discovery solutions.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/2223
Recent Developments:
In March 2024, Selvita S.A. has announced a strategic initiative to expand into biologic drug discovery and development, focusing on therapeutic antibody discovery. This move includes adding a skilled team and fully equipped laboratories to their service portfolio.
In May 2024, Insilico Medicine initiated the first in-patient dose for ISM8207, a novel small molecule inhibitor targeting QPCTL, co-developed with Fosun Pharma for treating advanced malignant tumors.
In June 2024, Certara, Inc., a global leader in model-informed drug development, has launched an updated version of the Simcyp Simulator for physiologically based pharmacokinetic (PBPK) modeling. This latest release introduces significant advancements designed to enhance decision-making capabilities for clients utilizing the simulator across all stages of drug development.
Segmentation of In-Silico Drug Discovery Market-
By Products:
Software
Software-as-a-Service (SaaS)
Consultancy-as-a-Service
By Workflow:
Discovery
o Target Identification
Bioinformatics
Reverse Docking
Protein Structure Prediction
o Target Validation
o Lead Discovery
Library Design
Pharmacophore
o Pre-Clinical Tests
o Clinical Trials
By Technology:
Artificial Intelligence
Graphics Processing Unit (GPU)
Other Technologies
o In-Silico Fishing
o RNN for Drug Design
By Software Type-:
Molecular modelling and de novo drug design software
Pharmacophore Modelling software
By End User:
Contract Research Organizations
Pharmaceutical and Biopharmaceutical Companies
Academic and Research Institutes
Others
By Region-
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of Middle East and Africa
For More Customization @ https://www.insightaceanalytic.com/customisation/2223
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Insight Ace Analytics
Diana Dsouza
+8884144123
diana.dsouza@insightaceanalytics.com
Source: EmailWire.Com 
|
